High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations.

Authors :: Xie Z
Fernandez J
Lasho TL
Finke CM
Amundson M
McCullough K
LaPlant B
Mangaonkar AA
Gangat N
Reichard KK
Elliott MA
Witzig TE
Patnaik MM
Source :: Blood [Blood] 2024 Oct 01. Date of Electronic Publication: 2024 Oct 01.
Publication Year :: 2024
Publisher :: Ahead of Print
Abstract: This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038.<br /> (Copyright © 2024 American Society of Hematology.)